Антиагрегантная терапия как средство вторичной профилактики ишемического инсульта

1. Гусев Е.И., Скворцова В.И. Ишемия головного мозга. М.: Медицина, 2001.
2. Гусев Е.И., Скворцова В.И., Стаховская Л.В. Эпидемиология инсульта в России. Журн. неврол. и психиатр. им. С.С.Корсакова. (Прил.). Инсульт. 2003; 8: 4–9.
3. Жетишев Р.Р., Камчатнов П.Р., Михайлова Н.А., Иващенко Р.А. Асимптомные инфаркты головного мозга: факторы риска и когнитивные нарушения. Журн. неврол. и психиатр. им. С.С.Корсакова. (Прил.). Инсульт. 2014; 3 (2): 3–7.
4. Клочихина О.А., Стаховская Л.В. Анализ эпидемиологических показателей инсульта по данным территориально-популяционных регистров 2009–2012 гг. Журн. неврол. и психиатр. им. С.С.Корсакова. 2014; 6: 46–52.
5. Скворцова В.И., Чазова И.Е., Стаховская Л.В. Вторичная профилактика инсульта. М.: ПАГРИ, 2002.
6. Суслина З.А. Сосудистая патология головного мозга: итоги и перспективы. Анналы клин. и эксперим. неврологии. 2007; 1 (1): 10–6.
7. Berrouschot J, Schwetlick B, von Twickel G et al. Aspirin resistance in secondary stroke prevention. Acta Neurol Scand 2006; 113 (1): 31–5.
8. Bhatt D, Flather M, Hacke W et al. Patients with prior myocardial infarction, stroke, or symptomatic peripheral arterial disease in the CHARISMA trial. J Am Coll Cardiol 2007; 49 (19): 1982–8.
9. Campbell C, Smyth S, Montalescot G et al. Aspirin Dose for the Prevention of Cardiovascular Disease. A Systematic Review JAMA 2007; 297: 2018–24.
10. Collet J, Himbert D, Steg P. Myocardial infarction after aspirin cessation in withdrawal. International. J Cardiol 2000; 76: 257–8.
11. Coull A, Lovett J, Rothwell P. Oxford Vascular Study. Population based study of early risk of stroke after transient ischemic attack or minor stroke: implications for public education and organization of services. BMJ 2004; 328: 326–8.
12. De Schryver E, van Gijn J, Kappelle L et al. Non-adherence to aspirin or oral anticoagulants in secondary prevention after ischaemic stroke. J Neurol 2005; 252 (11): 1316–21.
13. De Schryver E, Algra A, van Gijn J. Dipyridamole for preventing stroke and other vascular events in patients with vascular disease. Cochrane Database Syst Rev 2006; (2): CD001820.
14. Dickerson L, Carek P, Quattlebaum R. Prevention of recurrent ischemic stroke. Am Fam Physician 2007; 76 (3): 382–8.
15. Diener H, Bogousslavsky J, Brass L et al on behalf of the MATCH investigators. Aspirin and clopidogrel compared with clopidogrel alone after recent ischemic stroke or transient ischemic attack in high-risk patients (MATCH): randomised, double-blind, placebo-controlled trial. Lancet 2004; 364: 331–7.
16. Halkes P, van Gijn J, Kappelle L et al. ESPRIT Study Group. Aspirin plus dipyridamole versus aspirin alone after cerebral ischemia of arterial origin (ESPRIT): randomized controlled trial. Lancet 2006; 367 (9523): 1665–73.
17. Jones L, Griffin S, Palmer S et al. Clinical effectiveness and cost-effectiveness of clopidogrel and modified-release dipyridamole in the secondary prevention of occlusive vascular events: a systematic review and economic evaluation. Health Technol Assess 2004; 8 (38): 1–196.
18. Lee M, Saver J, Hong K et al. Risk-benefit profile of long-term dual- versus single-antiplatelet therapy among patients with ischemic stroke: a systematic review and meta-analysis. Ann Intern Med 2013; 159 (7): 463–70.
19. Lip G, Kamath S, Hart R. ABC of antithrombotic therapy: Antithrombotic therapy for cerebrovascular disorders. BMJ 2002; 325: 1161–3.
20.Antiplatelet Trialists' Collaboration. Collaborative overview of randomised trials of antiplatelet therapy-I: Prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patients. BMJ. Jan 8, 1994; 308(6921): 81–106.
21. Mees S, Rinkel G, Hop J еt al. Antiplatelet Therapy in Aneurysmal Subarachnoid Hemorrhage. A Systematic Review Stroke 2003; 34: 2285–9.
22. Michelson A, Cattaneo M, Eikelboom J еt al. Aspirin Resistance: Position Paper of the Working Group on Aspirin Resistance, Platelet Physiology Subcommittee of the Scientific and Standardization Committee of the International Society on Thrombosis and Haemostasis. J Thromb Haemost 2005; 3: 1–3.
23. Pulcinelli F, Pignatelli P, Celestini A et al. Inhibition of platelet aggregation by aspirin progressively decreases in long-term treated patients. J Am Col Cardiol 2006; 43 (6): 979–84.
24. Sacco RL, Foulkes MA, Mohr JP et al. Determinants of early recurrence of cerebral infarction. The Stroke Data Bank. Stroke 1989; 20: 983–9.
25. Sharma A, Khanna D, Balakumar P. Low-dose dipyridamole treatment partially prevents diabetes mellitus-induced vascular endothelial and renal abnormalities in rats. Int J Cardiol 2014; 172 (2): 530–2.
26. Thrift A, Cadilhac D, Thayabaranathan T et al. Global stroke statistics. Int J of Stroke 214; 9: 6–18.
27. Vermeer SE, Hollander M, Van Dijk E et al. Silent brain infarcts and white matter lesions increase stroke risk in the general population: the Rotterdam Scan Study. Stroke 2003; 34: 1126–9.
28. Diener HC, Cunha L, Forbes C et al. European Stroke Prevention Study 2. Dipyridamole and acetylsalicylic acid in the secondary prevention of stroke. Journal of the Neurological Sciences, 1996; 143: 1–13.

П.Р.Камчатнов1, Х.Я.Умарова2, А.В.Чугунов1

1 ГБОУ ВПО Российский национальный исследовательский медицинский университет им. Н.И.Пирогова Минздрава России, Москва;
2 ГБОУ ВПО Чеченский государственный университет, Грозный